Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y) | ANNALS OF ONCOLOGY |